期刊文献+

细胞周期蛋白D1基因G870A多态性与结直肠癌易感性的系统评价 被引量:2

Cyclin D1 G870A polymorphism and the risk of colorectal cancer: a systematic review
原文传递
导出
摘要 目的综合评价细胞周期蛋白D1(CyclinD1)基因G870A多态性与结直肠癌易感性的关系。方法通过CNKI、PubMed、EMCC等数据库检索文献,获得有关CyclinD,基因G870A多态性与结直肠癌危险性关系的研究结果,并通过Meta分析进行系统评价。所有文献均采用病例对照研究或者巢式病例对照研究,以OR值为效应指标,基因型在对照群体中的分布均符合Hardy—Weinberg遗传平衡定律,对文献进行评价筛选、异质性检验。本次Meta分析共纳入23项研究,累计病例6344例,对照9018例,利用RevMan5.0对各研究原始结果进行统计处理,对突变纯合子AA和杂合子GA基因型与纯合基因型GG进行比较,并计算合并OR值及其95%可信区间(cI)。结果AA和GA与GG基因型在病例组与健康对照组之间差异有统计学意义,OR=1.10(95%CI:1.01~1.19,P:0.02);按不同人群进行分层分析,亚洲人群OR=1.11(95%CI:0.98~1.26,P=0.11),美洲人群OR=1.13(95%CI:0.97~1.32,P=0.12),欧洲人群OR=1.06(95%CI:0.89—1.25,P=0.52),大洋洲人群OR=1.05(95%C1:0.80~1.38,P:0.73);按不同对照进行分组分析,医院基础OR=1.07(95%CI:0.95~1.20,P=0.28),人群基础OR:1.13(95%CI:1.01~1.26,P=0.04)。结论CyclinD1基因G870A多态性与结直肠癌易感性总体分析在统计学上具有相关性,按不同人群进行分组分析,都不支持具有相关性;按不同对照进行分组分析,以医院基础不具有相关性,以人群为基础具有相关性。 Objective To evaluate the association between Cyclin D1 Gg70A polymorphism and risk of colorectal cancer. Methods Extensive searches of relevant studies on datebase like PubMed, EMCC and CNKI were performed. Case control studies involving unrelated subjects and genotype frequencies in control group consist- ent with Hardy-Weinberg equilibrium were included for the meta-analysis. Twenty-three case-control studies with 6 344 cases and 9 018 controls were analyzed by the fixed-effect or random-effect meta-analysis method. The metaanalysis was applied with RevMan 5.0 software for heterogeneity test. AA and GA were compared with those with GG genotype. Pooled OR value and 95% confidence interval (CI) were calculated. Results There were statistical differences between AA & GA and GG. The pooled OR value was 1.10 (95% CI:I. 01-1.19, P =0. 02). The values were analyzed hierarchically according to different populations. The pooled OR value of Asian was 1.11 (95% (21: 0.98-1.26, P =0.11). The pooled OR value of American was 1.13(95%CI:0.97-1.32, P=0.12). The pooled OR value of European was 1.06(95%CI:0.89-1.25, P =0.52). The pooled OR value of Oceanian was 1.05(95%CI: 0. 80-1.38, P = 0. 73). The values were analyzed hierarchically according to the comparison basis. The pooled OR value of hospital-based was 1.07(95% CI:O. 95-1.20, P =0.28). The pooled OR value of population-based was 1.13 (95% CI:I. 01-1.26, P =0. 04). Conclusion The Cyclin D1 G870A pelymorphism is correlated with the suscepti- bility of colorectal cancer risk at the aggregate level analysis. Analysis by different methods : according to different populations, every group don't support the correlation. According to comparison basis, there has no correlation in hospital-based group, but there has correlation in population-based group.
出处 《国际肿瘤学杂志》 CAS 2012年第5期395-400,共6页 Journal of International Oncology
关键词 结直肠肿瘤 细胞周期蛋白D1 G870A多态性 META分析 Colorectal neoplasms Cyclin D1 G870A polymorphism Meta anaiysis
  • 相关文献

参考文献36

  • 1Jemal A, Bray F, Center MM. Global cancer statistics. CA Cancer J Clin, 2011, 61 (2):69-90.
  • 2Solomon DA, Wang Y, Fox SR, et al. Cyclin D1 splice variants. Dif- ferential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem, 2003, 278(32) :30339-30347.
  • 3Bahnassy AA, Zekri AR, E1-Houssini S, et al. Cyclin A and eyclin D1 as significant prognostic markers in colorectal cancer patients. BMC Gastroenterol, 2004, 4:22.
  • 4Hosokawa Y, Tu T, Tahara H, et al. Absence of cyclin D1/PRADI point mutations in human breast cancers and parathyroid adenomas and identification of a new cyelin D1 'gene polymorphism. Cancer Lett, 1995, 93(2) :165-170.
  • 5Lu C, Dong J, Ma H, et al. CCND1 G870A polymorphism contrib- utes to breast cancer susceptibility: a recta-analysis. Breast Cancer Res Treat, 2009, 116 (3) :571-575.
  • 6Li Z, Jiao X, Wang C, et al. Ahernative cyclin DI splice forms dif- ferentially regulate the DNA damage response. Cancer Res, 2010, 70 (21) :8802-8811.
  • 7Knudsen KE, Diehl JA, Haiman CA, et al. Cyclin DI: polymor- phism,aberrant splicing and cancer risk. Oncogene, 2006, 25 ( 11 ) : 1620-1628.
  • 8Kong S, Wei Q, Amos CI, et al. Cyclin D1 polymorphism and increased risk of colorectal cancer at young age. J Natl Cancer Inst, 2001, 93(14) :1106-1108.
  • 9Probst-Hensch NM, Sun CL, Van Den Berg D, et al. The effect of the cyclin D1 (CCNDI) A870G polymorphism on eolorectal cancer risk is modified by glutathione-S-transferase polymovphisms and iso- thiocyanate intake in the Singapore Chinese Health Study. Carcino- genesis, 2006, 27(12) :2475-2482.
  • 10Le Marchand L, Seifried A, Lum-Jones A, et al. Association of the cyclin D1 A870G polymorphism with advanced colorectal cancer. JAMA, 2003, 290(21 ) : 2843-2848.

二级参考文献23

  • 1Bahnassy AA, Zekri AR, El-Houssini S, et al.Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients[J]. BMC Gastroenterol, 2004, 4:22.
  • 2Knudsen KE, Diehl JA, Haiman CA, et al.Cyclin D1: polymorphism, aberrant splicing and cancer risk[J]. Oncogene, 2006, 25(11): 1620- 1628.
  • 3Tan XL, Nieters A, Kropp S, et al. The association of cyclin D1 G870A and E-cadherin C-160A polymorphisms with the risk of colorectal cancer in a case control study and meta-analysis[J]. Int J Cancer, 2008, 122(11):2573-2580.
  • 4Huang WS, Tang R, Lin PY, et al. Impact of the cyclin D1 A870G polymorphism on susceptibility to sporadic colorectal cancer in Taiwan[J]. Dis Colon Rectum, 2006, 49(5):602-608.
  • 5Schernhammer ES, Tranah GJ, Giovannucci E, et al. Cyclin D1 A870G polymorphism and the risk of colorectal cancer and adenoma[J]. Br J Cancer, 2006, 94(6):928-934.
  • 6Kong S, Wei Q, Amos CI, et al. Cyclin D1 polymorphism and increased risk of colorectal cancer at young age[J]. J Natl Cancer Inst, 2001, 93(14): 1106-1108.
  • 7Hong Y, Eu KW, Seow-Choen F, et al. GG genotype of cyclin D1 G870A polymorphism is associated with increased risk and advanced colorectal cancer in patients in Singapore[J]. Eur J Cancer, 2005, 41(7):1037-1044.
  • 8Le Marchand L, Seifried A, Lum-Jones A, et al. Association of the cyclin D1 A870G polymorphism with advanced colorectal cancer[J]. JAMA, 2003, 290(21): 2843-2848.
  • 9Yoshiya G, Takahata T, Hanada N, et al. Influence of cancer-related gene polymorphisms on clinicopathological features in colorectal cancer[J]. J Gastroenterol Hepatol, 2008, 23(6): 948-953.
  • 10Zhang W, Gordon M, Press OA, et al. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab[J]. Pharmacogenet Genomics, 2006, 16(7): 475-483.

共引文献5

同被引文献25

  • 1邓可刚.循证医学证据的检索步骤与检索系统的选择[J].中国循证医学杂志,2004,4(9):634-637. 被引量:26
  • 2章宏,厉有名,虞朝辉,王升启,季峰,陈春晓.肿瘤患者二氢嘧啶脱氢酶基因多态性与5-氟尿嘧啶毒副反应的关系[J].中华内科杂志,2007,46(2):103-106. 被引量:14
  • 3Holma R, Korpela R, Sairanen U, et al. Colonic methane produc- tion modifies gastrointestinal toxicity associated with adjuvant 5- Fluorouracil chemotherapy for colorectal cancer [ J ]. J Clin Gastro- enterol, 2013,47( 1 ) :45-51.
  • 4Li J, Hou N, Faried A, et al. IInhibition of autophagy augments 5- fluorouracil chemotherapy in human colon cancer in vitro and in vi- vo model [ J ]. Eur J Cancer, 2010,46 (10) : 1900-1909.
  • 5Di Paolo A, Lencioni M, Amatori F, et al. 5-fluorouracil pharma- cokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer [ J]. Clin Cancer Res, 2008,14(9) :2749-2755.
  • 6Schwab M, Zanger UM, Marx C, et al. Role of genetic and nonge- netic factors for fluorouracil treatment-related severe toxicity : a pro- spective clinical trial by the German 5-FU Toxicity Study Group [J]. J Clin Oncol, 2008,26(13) :2131-2138.
  • 7Teh LK, Hamzab S, Hashim H, et al. Potential of dihydropyrimi- dine dehydrogenase genotypes in personalizing 5-Fluorouracil thera- py among eolorectal cancer patients [ J]. Ther Drug Monit, 2013, 35 (5) :624-630.
  • 8Kaldate RR, Haregewoin A, Gricr CE, et al. Modeling the 5-flu- orouracil area under the curve versus dose relationship to develop apharmacokinetic dosing algorilhm for colorectal cancer patients re- ceiving FOLFOX6 [ J ]. Oncologist, 2012,17 ( 3 ) : 296 -302.
  • 9Kristensen MH, l%dersen PL, Melsen GV, et al. Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reduc- tase and thymidylate synthase genes predict early toxicity of 5-flu- orouracil in colorectal cancer patients [ J]. J Int Med Res, 2010, 38(3) :870-883.
  • 10Teh LK, Hamzah S, Hashim H, et al. Potential of dihydropyrimi- dine dehydrogenase gcnotypes in personalizing 5-fluorouracil thera- py among eoloreetal cancer patients [ J 1. Ther Drug Monit, 2013, 35 (5) :624-630.

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部